Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE versus QDOLO.
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semisynthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Homatropine methylbromide is an anticholinergic agent that reduces gastrointestinal motility and secretions.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Oral: 5 mg hydrocodone/1.5 mg homatropine every 4 to 6 hours as needed; maximum 30 mg hydrocodone per day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
The terminal elimination half-life of hydrocodone is approximately 3.8-4.5 hours in adults, though it may be prolonged in hepatic impairment or elderly patients. Homatropine methylbromide has a half-life of about 2-3 hours.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Hydrocodone and its metabolites are primarily excreted renally. Approximately 60% of a dose is eliminated in urine as unchanged drug and conjugates, with less than 5% excreted in feces. Homatropine methylbromide is a quaternary ammonium compound that is poorly absorbed and excreted mainly unchanged in feces via biliary elimination.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist